Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02548143 · ClinicalTrials.gov registry record · Phase 3
LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures
A Phase 3 study, sponsored by Laboratoire français de Fractionnement et de Biotechnologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
NCT02548143 is a Phase 3 study that has completed, run by Laboratoire français de Fractionnement et de Biotechnologies. The registered enrollment target is 12 participants.
The verdict
NCT02548143, a Phase 3 study, has completed, sponsored by Laboratoire français de Fractionnement et de Biotechnologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study, PerSept 3, is to evaluate LR769 for the prevention of excessive bleeding and achievement of hemostasis in congenital hemophilia A or B patients who have inhibitors to Factor VIII or Factor IX , are aged 6 months to 75 years, inclusive; and who are undergoing elective surgical or other invasive procedures. Administration of LR769 will be performed just prior to surgery/procedure and will be repeated during and after the surgery/procedure to achieve and maintain adequate hemostasis as determined by the investigator's judgment.
Interventions
- BIOLOGICAL Coagulation Factor VIIa (Recombinant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-08-25 |
| Est. Completion | 2017-08-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02548143
The ClinicalTrials.gov registry entry for NCT02548143 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laboratoire français de Fractionnement et de Biotechnologies, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Coagulation Factor VIIa (Recombinant) is the first listed.
NCT02548143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02548143 about?
NCT02548143 is a clinical study titled "LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures". The purpose of this study, PerSept 3, is to evaluate LR769 for the prevention of excessive bleeding and achievement of hemostasis in congenital hemophilia A or B patients who have inhibitors to Factor VIII or Factor IX , are aged 6 months to 75 years, inclusive; and who are undergoing elective surgi...
What is the current status of trial NCT02548143?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2016-08-25. Estimated completion is 2017-08-31.
What interventions are being tested in trial NCT02548143?
The interventions under investigation include: Coagulation Factor VIIa (Recombinant) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02548143?
This trial is sponsored by Laboratoire français de Fractionnement et de Biotechnologies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.